Adma Biologics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Adma Biologics has 3 disclosed suppliers and 4 disclosed customers in SEC filings.
+8.64%
vs ±11.7% implied · ×0.74
shaded = implied · ▲▼ = realized
Adma Biologics, Inc.
11.41
SentenceEffective October 1, 2024, we entered into an Amended and Restated Plasma Purchase Agreement with Grifols (the "A&R Grifols Agreement") with a term expiring in September 2039, after which it may be renewed for two additional multi-year periods if agreed to by the parties.
Sentence* Pursuant to a shared services agreement, as amended, with Areth, LLC ("Areth") for office, warehouse space and related services pursuant to which the Company pays Areth monthly lease payments of $10,000.
ADMA 10-Kaccession 0001140361-25-009257
SentenceEffective August 6, 2024, we entered into a Plasma Purchase Agreement with KEDPlasma LLC ("KEDPlasma") with a term expiring in July 2031, after which it may be renewed for an additional multi-year period if agreed to by the parties (the "KEDPlasma Agreement").
ADMA 10-Kaccession 0001140361-26-006815
SentenceFor the years ended December 31, 2025 and 2024, two customers, BioCare, Inc. ("BioCare") and Priority Healthcare Distribution, Inc. d/b/a CuraScript SD Specialty Distribution ("CuraScript"), represented an aggregate of approximately 73% and 72%, respectively, of our consolidated revenues.
ADMA 10-Kaccession 0001140361-26-006815
SentencePursuant to our Manufacturing, Supply and License Agreement effective as of December 2012, we granted to Biotest AG ("Biotest") an exclusive license to market and sell ASCENIV in Europe and in certain countries in Northern Africa and the Middle East (the "Territory"), to have access to our testing services for testing of Biotest's plasma samples using our proprietary RSV assay, and to reference (but not access) our proprietary information for the purpose of Biotest seeking regulatory approval for ASCENIV in the Territory.
ADMA 10-Kaccession 0001140361-26-006815
SentenceFor the year ended December 31, 2025, two customers, BioCare, Inc. ("BioCare") and Priority Healthcare Distribution, Inc. ("CuraScript"), represented an aggregate of approximately 73% of our consolidated revenues.
ADMA 10-Kaccession 0001140361-26-006815
SentenceFor the years ended December 31, 2025 and 2024, two customers, BioCare, Inc. ("BioCare") and Priority Healthcare Distribution, Inc. d/b/a CuraScript SD Specialty Distribution ("CuraScript"), represented an aggregate of approximately 73% and 72%, respectively, of our consolidated revenues.
ADMA 10-Kaccession 0001140361-26-006815
Largest filed tie
—
Expected move
Inputs8Q avg ±8.0%·×0.20·cheap
straddle ±11.0%
spot 11.41exp Nov 20ATM strike 11ATM straddle 1.47IV 67%